$1,000 minimum
completed of $250,000
$4,000 currently processing
days to go

For Accredited Investors only.

MedWorxs is a privately-held international leader in inpatient and ambulatory software solutions. Our cloud based technology is modern in design, delivering the right features for medical organizations. We meet the requirements for multiple facility settings and specialties. Whether it’s our Federally Certified Facility based Health Records, Practice Management, Federally certified Physician’s Office Electronic Health Records or our award winning Revenue Cycle Management, we can provide the right solutions. 

These solutions are proven and a strong foundation for future acquisition conversions.


The objective of MedWorxs is to grow rapidly through focused, targeted acquisitions of quality businesses with built in recurring revenue returning strong valuations to our shareholders.

Quality acquisition targets within the US are abundant. We are searching for capital to close these deals while the consolidation is occurring.

MedWorxs has the systems, infrastructure and team to continue our acquisition strategy. Through a very solid, proven model we are poised for continue revenue expansion.


  • MedWorxs has been profitable since it was founded 16 years ago
  • Strong recurring revenue model with very high predictability
  • Experienced, progressive, proven management team
  • Proven growth strategy. Five acquisitions completed and successfully integrated
  • Base of acquisition targets to drive further growth is large
  • Three additional acquisition deals negotiated. Due diligence process has begun, Letters of intent signed and in hand
  • De-risked because team has in house tech, own our datacenter, software systems and infrastructure,
  • Our performance generates 20x lifetime customer value relative acquisition costs is dramatically better than traditional organic Saas Growth
  • Business Development capability with proven track record!



  • All proceeds will be      strictly used to continue our acquisition strategy with an ultimate goal      of raising $1 million for phase 1. Please reference the term sheet for      greater detail



Our solutions have been specifically designed with the healthcare organization in mind. Ease of use, simple to learn and manage. We meet the requirements for multiple Inpatient settings and specialties, whether it’s our Fully Certified Inpatient Health Records, Practice Management, Fully certified Ambulatory Electronic Health Records or our award winning Revenue Cycle Management. We can provide the right solutions.

Meet the Team
No news yet, please stay tuned.
2 total, 1 anonymous
General Risks
By accessing this site you agree to be bound by FrontFundr’s Terms and Conditions and Privacy Policy. FrontFundr distributes exempt market securities to qualified individuals as defined by National Instrument 45-106, Prospectus and Registration Exemptions and crowdfunding exemptions including Multilateral Instrument 45-108 Crowdfunding and Multilateral CSA Notice 45-316 Start-up Crowdfunding Registration and Prospectus Exemptions.
As an exempt market dealer, Silver Maple can trade and underwrite exempt market securities. Exempt market securities are risky investments and you could lose all the money you invest in such securities.
In general, investment products sold in the exempt market are considered high risk because:
  1. They are not covered by deposit or investor protection insurance;
  2. Regulators do not review offering memoranda for completeness;
  3. Private issuers are not subject to the same ongoing disclosure obligations as reporting issuers;
  4. Private issuers may inadvertently, or advertently, refrain from providing an investor or a registered dealer, all the information required to make an informed investment decision.
  5. Many exempt products are not as liquid as publicly-traded securities and you may be restricted in your ability to sell or transfer these securities; and
  6. Exempt products are often subject to a greater degree of “key person” risk than more widely held securities.
  7. There can be no assurances that an investment will maintain its net acquisition value or produce any projected income or capital return. Investment values change frequently and past performances may not be repeated.
  8. Using borrowed money to finance the purchase of securities involves greater risk than a purchase using cash resources. If you borrow money to purchase securities, your responsibility to repay the loan and pay interest as required by its terms remains the same even if the value of the securities purchased declines. See “use of borrowed funds”.
The risks highlighted above are not conclusive. Risk disclosures specific for each offering are reviewed by SMV and are presented within an issuer’s profile page on the platform and within the offering memorandum or other offering documents for the issuance. Offering documents and the risks associated with the securities of an issuer contained therein should be reviewed thoroughly by an investor or an investor’s professional advisors before making an investment.
This web site is for general information only and is not intended to provide personalized advice, including investment, financial, legal, accounting or tax advice. FrontFundr will assess your suitability to invest in the products offered on its platform.

MedWorxs Inc

Term Sheet 

Common Stock Offering 

September 5, 2018

This Term Sheet represents the current understanding of the parties with respect to certain of the major issues relating to the proposed private offering and does not constitute a legally binding agreement. Except for this summary does not constitute a legally binding obligation. Any other legally binding obligation will only be made pursuant to definitive agreements to be negotiated and executed by the parties. This Term Sheet does not constitute an offer to sell or a solicitation of an offer to buy securities in any jurisdiction where the offer or sale is not permitted. 

*All currency in Canadian Dollars


MedWorxs Inc (the “Company”)

Type of Security: 

Common Stock

Pre-Money Valuation:


Offering Size: 

The Company intends to raise as much as $1,000,000   in this offering, although the Company may increase or decrease this amount   in its sole discretion. 

Price Per Share: 

$0.05 per share

Minimum Investment: 

$1,000 (may be waived by the Company in its sole   discretion)

Shares Authorized to be sold in this Offering:



When, as and if declared by the Board.The Company has not paid dividends in the   past and does not currently contemplate that it will pay dividends in the   future.

Voting Rights: 

All shares have the same voting rights.

Investor Eligibility: 

Accredited Investors” only. 


The Company will provide additional information upon   request. 


One or more closings as the Company accepts   subscriptions. 

Use of Proceeds: 

Working capital; proceeds will be immediately   available to the Company. 

Subscription Procedure: 

Investors must   execute a Common Stock Purchase Agreement, which will include a right of   first refusal agreement in favor of the Company on any proposed transfers of   Common Stock purchased in the offering.

Amount RaisedPercent of Equity OfferedPost-money ValuationPre-Money Valuation
$1,000,000 12%$8,500,000 $7,500,000 
$250,000 3%$7,750,000 $7,500,000 
Get in Touch
(720) 961-4045